Skip to content

Cytokinetics

US · CYTK #1564 by market cap Listed 1970
50.78 -0.68 -1.32%
Periodic snapshot; not a real-time feed. · 2026-11-20 20:02

About Cytokinetics

Cytokinetics, Inc. is a biopharmaceutical company, which is focused on discovering, developing, and commercializing muscle activators and muscle inhibitors as potential treatments for people with debilitating diseases in which muscle performance is compromised and/or declining. The firm is developing small molecule drug candidates specifically engineered to impact muscle function and contractility. Its clinical-stage drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator, CK-136, a novel cardiac troponin activator, reldesemtiv, a novel fast skeletal muscle troponin activator, aficamten, a novel cardiac myosin inhibitor, and CK-3772271, a novel cardiac myosin inhibitor. The company was founded by Ronald D. Vale, Lawrence S. B. Goldstein, James H. Sabry, and James A. Spudich in 1997 and is headquartered in South San Francisco, CA.

Founded
1997
CEO
Mr. Robert I. Blum
Employees
673
Headquarters
South San Francisco, California, United States of America
Fiscal year end
12-31
Website
cytokinetics.com

Company profile

Exchange
US
Symbol
CYTK
Market-cap rank
#1564
Listing date
1970-01-01
Market cap
7.07B
Float cap
7.05B
Shares out
139.30M
Float shares
138.78M

Sectors & themes

Biotechnology Fractional Shares JP

Browse all sectors & themes

Quote time 2026-11-20 20:02:43 · For reference only, not investment advice and not tailored to your situation.

Cytokinetics discussion 0 comments

Add a comment